MBX Biosciences, Inc. Common Stock
General ticker "MBX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.0B (TTM average)
MBX Biosciences, Inc. Common Stock follows the US Stock Market performance with the rate: 47.2%.
Estimated limits based on current volatility of 2.1%: low 65.54$, high 68.29$
Factors to consider:
- Total employees count: 63 (-100.0%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Capital raising, Labor/talent shortage/retention, IP protection failure
- Current price 68.6% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [15.41$, 39.34$]
- 2026-12-31 to 2027-12-31 estimated range: [9.29$, 25.56$]
Short-term MBX quotes
Long-term MBX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $35.31MM | $68.19MM | $98.06MM |
| Operating Income | $-35.31MM | $-68.19MM | $-98.06MM |
| Non-Operating Income | $2.75MM | $6.27MM | $11.08MM |
| R&D Expense | $28.53MM | $57.41MM | $79.16MM |
| Income(Loss) | $-32.56MM | $-61.92MM | $-86.97MM |
| Net Income(Loss)* | $-32.56MM | $-61.92MM | $-86.97MM |
| Stockholders Equity | $-72.47MM | $257.44MM | $369.22MM |
| Assets | $84.18MM | $268.54MM | $385.14MM |
| Operating Cash Flow | $-31.98MM | $-54.68MM | $-79.95MM |
| Capital expenditure | $0.13MM | $0.87MM | $1.93MM |
| Investing Cash Flow | $-30.93MM | $-160.59MM | $-83.70MM |
| Financing Cash Flow | $69.22MM | $234.10MM | $189.59MM |
| Earnings Per Share** | $-1.02 | $-1.85 | $-2.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.